US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.
2025-11-04
US biotechnology company Metsera: Novo Nordisk (NVO.N)'s offer is better than Pfizer's (PFE.N) revised proposal, which values the company at up to $70 per share, totaling approximately $8.1 billion.